Biotech Values

[vinmantoo]

"For those interested, this is a compound that ONXX has a financial interest in. ONXX likely gets 5% or less in royalties, but I've not come across any explicit mention of the cut."

Thanks for the info poorgradstudent. I thought the CDK inhibitor from PFE sounded familiar. Less than 5% is a small number but I am not going to look down my nose at new revenues that will come into ONXX if PFE gets the CDK inhibitor approved.